SecBot SecBot
PRESS-RELEASE ·Filed Nov 12, 2026

PROK

ProKidney
BEARISH
Impact 7/10
Horizonweeks Processed4d 10h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

The simultaneous ATM filing signals urgent capital needs despite stated cash runway into mid-2027. Monitor for ATM drawdowns and any delays in PROACT 1 enrollment or data readout that could accelerate cash burn.

DirectionBearish
Confidencehigh
Horizonweeks

REACT

● Neutral Named in this press release
Impact
Phase
Phase 3
Time to market
If Phase 3 PROACT 1 data is positive in Q2 2027 and an accelerated approval filing follows, a potential FDA decision could come in late 2027 or 2028. Commercial launch would follow approval.
Next catalyst
None dated

What to watchThe next major catalyst is the Phase 3 PROACT 1 topline data readout, expected in Q2 2027. Positive results could unlock an accelerated approval filing under FDA's RMAT pathway, while a miss would likely devastate the stock given the company is a single-asset developer. A softer near-term event is the KOL virtual event on October 27, 2026, which may provide updated mechanism-of-action data from ASN Kidney Week.

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+1
Entry
$1.05
T+0 close · Nov 12, 2026 · via day close
Latest settled
−0.48%
T+1 · $1.04
Vs SPY
+1.43%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $1.05entry
  2. T+1 · 20h ago −0.48%α +1.43% · $1.04
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

ProKidney reported Q3 2026 results with no revenue and a net loss of $51.8 million, while cash burn continues with $141.9 million in cash providing runway into mid-2027. The company also filed a $200 million at-the-market equity facility on the same day, representing potential dilution of up to 86% of current shares outstanding.

Key Financial Metrics

EPS
−$0.17
Revenue
$174.0K
est $125.0K · +39.2% · -19.8% YoY

Key Facts

  • Cash and marketable securities fell to $141.9 million from $181.6 million at Q2 2026
  • Net loss before noncontrolling interest was $51.8 million for Q3 2026 vs $35.8 million in Q3 2025
  • R&D expenses rose to $40.8 million from $26.8 million year-over-year
  • Filed a $200 million ATM equity facility on the same day as this press release
  • ATM program represents potential dilution of up to 86% of current shares outstanding at $1.13 reference price
  • Cash runway into mid-2027; no approved products and no revenue
  • Phase 3 PROACT 1 full enrollment expected Q1 2027, topline eGFR slope data in Q2 2027

Financial Impact

Cash burn of $39.7 million in Q3 2026; $200 million ATM facility represents up to 86% dilution of current shares

cashdilutionnet lossR&D expenses

Risk Factors

  • Potential dilution of up to 86% from the ATM facility
  • Cash runway only into mid-2027 with no revenue and increasing R&D costs
  • Clinical trial risk: PROACT 1 data readout in Q2 2027 is binary for stock valuation

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
69% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3402235

Track record

13 reports on PROK

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +13.51% at T+1 after the Oct 29, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 12, 20264d ago Press Release Bearish 7/10 Viewing Entry $1.05 to $1.04 Now $1.04 +0.48% ▲ +0.48% −1.43% vs SPY
  2. Nov 12, 20264d ago 424B5 Bearish 6/10 Entry $1.15 to $1.05 Now $1.04 +9.57% ▲ +9.13% +8.77% vs SPY
  3. Nov 12, 20265d ago EFFECT Bearish 5/10 Entry $1.15 to $1.05 Now $1.04 +9.57% ▲ +9.13% +8.77% vs SPY
  4. Nov 9, 20267d ago 8-K Neutral 3/10 Entry $1.15 to $1.11 Now $1.04 −9.57% ▼ −3.48% −3.11% vs SPY
  5. Oct 29, 202618d ago 8-K Bearish 6/10 Entry $1.30 to $1.12 Now $1.04 +19.69% ▲ +13.51% +13.03% vs SPY
  6. Oct 29, 202618d ago S-3 Bearish 6/10 Entry $1.30 to $1.12 Now $1.04 +19.69% ▲ +13.51% +13.03% vs SPY
  7. Oct 22, 202625d ago Press Release Neutral 3/10 Entry $1.43 to $1.41 Now $1.04 −27.27% ▼ −1.40% −0.88% vs SPY
  8. Aug 10, 202614w ago 8-K Neutral 5/10 No price data
  9. Aug 10, 202614w ago Press Release Neutral 5/10 Entry $1.61 to $1.48 Now $1.04 −35.40% ▼ −8.07% −8.32% vs SPY
  10. May 15, 202626w ago 8-K Neutral 4/10 No price data
Showing 10 of 13

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026